Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow bluebird bio, Inc.

Get SEC filing alerts via email and in your feed for bluebird bio, Inc.

BLUE

bluebird bio, Inc.

About bluebird bio, Inc.

Bluebird bio, Inc. is a biotechnology company specializing in developing and commercializing gene therapies for severe genetic diseases. Its core focus is on innovative lentiviral vector-based treatments for conditions like sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. The company’s products aim to provide lifelong cures through one-time treatments, leveraging proprietary technology, extensive clinical data, and a specialized treatment center network.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from bluebird bio, Inc.

1
1
bluebird bio, Inc. bluebird bio Reports $38.7M Revenue and Plans Merger with Beacon Parent Holdings

Via official filing (AI summary) | about 1 year ago | 0 comments

2
1
bluebird bio, Inc. bluebird bio Reports Revenue Growth to $83.8 Million Amid Increased Gene Therapy Infusions

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
bluebird bio, Inc. bluebird bio Reports Significant Financial Decline, Net Loss Widens in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments

4
1
bluebird bio, Inc. bluebird bio Reports 135% Increase in Product Revenue, Widened Net Loss in Q2 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

5
1
bluebird bio, Inc. bluebird bio Reports Significant Net Loss and Financial Challenges in Q1 2024

Via official filing (AI summary) | almost 2 years ago | 0 comments